Valsartan

8 Drugs classified under this active ingredient

Angiotensin II Antagonist, Thiazide. Valsartan 80 mg, 160 mg, Hydrochlorothiazide 12.5 mg, 25 mg.
CO-DIOVAN 80: F.C. TABS: 28. 1 tab dly. Max. effect within 2-4 wks.
Hypertens. when comb. ther. appropriate.
CO-DIOVAN 160: F.C. TABS: 28. 1 tab dly.
Hypertens., when blood pressure not adequat. controlled by monother. To be used as second-line ther.
C/I: Hypersens. Hypersens. to sulfonamide-derived med. products. 2^nd & 3^rd trim. of preg. Biliary cirrhos. and cholestasis. Pts. with anuria. Refractor. hypokalaemia, hyponatraemia, hypercalcaemia, and symptomat. hyperuricaemia. Concom. use with aliskiren-contain. products in pts. with diab. mell. or renal impair. (GFR <60 mL/min/1.73m²).

Angiotensin II Antagonist. Valsartan 40, 80 ,160 mg.
F.C. TABS.: 28. Hyperten.: 80 mg×1/d most
pts. The antihypertens. effect is
substantial. present within 2 wks. and
max. effects are seen after 4 wks.
In some pts. whose blood press. is not
adequate. control., the dose may be
incr. to 160 mg, or a greater decr. in BP
may be achieved by add. in a thiazide
diuret. See lit.
Heart fail.: 40 mg ×1/d.
Uptitration to 80 mg, 160 mg×2/d
should be done to the highest dose
tolerat. by the pt.
Considerat. should be given to
reducing the dose of concom. diuret.
The max. dly. dose admin. in clin. trials
is 320 mg in divided doses. See lit.
Post-MI.: Achievem. of the target dose
of 160 mg×2/d should be based on the
pt’s tolerab. to valsartan during titrat. If
symptomat. hypotension or renal
dysfunct. occurs, consider. should be
given to a dosage reduct. See lit.
Therapy may be init. as early as 12 hrs.
after a MI . After an initial dose of 20 mg ×2/ d, valsartan ther. should be
titrated to 40 mg, 80 mg, and 160 mg
×2/ d over the next few wks. The start.
dose is provided by the 40 mg divisible
tab.
Tmt. of hypertens.: 80 mg and 160 mg.
Heart fail. : 40 mg, 80 mg and 160 mg
Tmt. of heart fail.(NYHA class II‐IV) in pts.
who are intoler. of angiotens. Convert.
enzyme inhib. See lit.
Post-myocard. infarction (40 mg, 80 mg
and 160 mg)
Indicat. to improve survival follow.
myocard.l infarct.in clinical. stable pts.
with signs, sympt. or radiolog. evidence
of left ventric. fail. and/or with left
ventric. systolic dysfunct. See lit.
C/I: Known hypersens. to valsartan or to
any of the excip. Preg., and lact.
Sev. hepatic impair., cirrhosis, biliary
obstruct. Concom. use of angiotensin
recept. antagonists (ARBs) ‐ includ.
valsartan ‐ or of ACEIs with aliskiren is
contraind. in pts. with diab. mell. or renal
impair.(GFR < 60 ml/min/1.73 m²). See
lit.

Angiotensin II Antagonist, Plain Combinations with Dihydropyridine Derivatives. Amlodipine Besylate 5 mg, 10 mg, Valsartan 80 mg, 160 mg.
COATED TABS.: 28 x 5 mg/80 mg,
5 mg/160mg; 10 mg/160 mg.
1 tab dly. Individ. dosetitrat. with
components recommend. before changingto fixed dose comb.Max. dose is 10/320 mg.
Tmt. of essential hypertens., for pts.
whose blood pressure is not adeq.
controlled on monotherapy.
C/I: Hypersens.toamlodopine, valsartan,
todihydropyridinederivat.; Severe hep.
impair., cholestasis; Severe renal impair.
and pts. underg. dialysis;
Preg.; Concom. use of ARBs or ACEIs with
aliskiren in pts. with diabet.

Angiotensin II Antagonist, Other Combinations. Sacubitril 24, 49, 97 mg, Valsartan (as sodium salt complex) 26, 51, 103 mg.
F.C. TABS: 28×50 mg, 56×100 mg, 56×200 mg. Init. dose: 1 tab (100 mg)×2/d, The dose should be doubled (in certain situation.) after 2-4 wks. to the target maint. dose of 1 tab. of 200 mg twice dly., as tolerated by the pt. See lit.
Tmt. of heart fail. (NYHA class II-IV) in pts. with syst. dysfunc. This formulation has been shown to reduce the rate of cardiovasc. death and heart fail. hospitalis. compared to ACE inhib. therapy.
C/I: Hypersens. Concom. use with ACE inhib. , ust not be admin. until 36 hrs. after discount. ACE inhib. ther. Known hist. of angioed.related to prev.ACE inhib. or ARB therapy. Hered. or idiopath. angioed. Concom. use with aliskiren-contain. med. products in pts. with diabetes mell. or in pts. with renal impair. (eGFR <60 ml/min/1.73 m2). Severe hep. impair., biliary cirrhosis and cholestasis. 2nd, 3rd trimes. of preg. Pts. with serum K+ level >5.4 mmol/l or with SBP <100 mmHg.

Angiotensin II Antagonist, Calcium Channel Blocker. Amlodipine Besylate 5 mg, 10 mg, Valsartan 80 mg, 160 mg.
F.C. TABS: 14, 28 x 5 mg/80 mg, 5
mg/160mg, 10 mg/160 mg. 1 tab dly
with or without food. Individ. dose
titrat. recommend. bef. change to fixed
dose comb.
Essential hypertens. not adeq. controlled
on monother.
C/I: Known hypersens.to amlodopine,
valsartan, to dihydropyridine derivat.
Sev. hep. impair. bil. chirrhos., cholestas.
Sev. ren. impair.(GFR < 30 ml/min/1.73
m2),pts. underg. dialys., Preg. ., concom.
use with aliskiren in pts. with diab.
mellit.or ren.impair.(GFR < 60 ml/
min/1.73 m2).

Angiotensin II Antagonist. Valsartan 80 mg, 160 mg.
F.C TAB.: 28. Hypertens.: The recomm. dose
of Valsartan is 80 mg ×1/d for most pts.
The antihypertens. effect is substant.
present within 2 wks. and max. effects
are seen after 4 wks. In some pts.
whose blood pres. is not adequate.
control. the dose may be increased to
160 mg, or a greater decr. in BP may be
achiev. by add. in a thiazide diur.
Valsartan may also be admin. with
other antihypertens. agents.
Use in pts. over 75 yrs.:
A lower start. dose of 40 mg once dly. is
recom.
Tmt. of HF (NYHA class II-IV) in pts. who
are intoler. of ACE inhib.
In a control. clinical trial Valsartan
signific. reduced hospitalisations for
heart fail.
There is no evid. that Valsartan provides
added benefits when it is used with an
adequate dose of an ACE inhib.
Indicated to improve surviv. follow. MI in
clinical. stable pts. with signs sympt. or
radiolog. evid. of left ventric. fail. and /or
with left ventric. systole. dysfunct.
For tmt. of hypertens.
C/I: Hypersens. Preg.
Sev. hep. dis., sev. hep. dysfunc., cirrhosis
of the hep/ bil. obstruct.
Pts. with diabetes or impair. renal funct.
and are concom. taking a antihypertens. formul. contain. aliskiren.